Literature DB >> 1673261

Mechanisms of disease in Hantavirus infection: pathophysiology of hemorrhagic fever with renal syndrome.

T M Cosgriff1.   

Abstract

Hemorrhagic fever with renal syndrome (HFRS) is an acute viral disease that occurs over wide areas of Europe and Asia. Hantaviruses are the cause of this syndrome. The hallmark of HFRS is the triad of fever, hemorrhage, and renal failure. In its severe form it is associated with significant mortality. The syndrome evolves through five phases: febrile, hypotensive, oliguric, diuretic, and convalescent. The central physiologic derangement in HFRS is vascular dysfunction, manifested by impaired vascular tone and increased vascular permeability. The systemic effects of this dysfunction account for the occurrence of hypotension and shock, while local effects are probably important in the development of renal failure. Shock in HFRS has distributive and oligemic features, while renal failure has features of acute tubular necrosis. Hemorrhage is a consequence of vascular injury and a deficit of functional platelets. Vascular and platelet dysfunction are both compounded by uremia. Disseminated intravascular coagulation contributes to hemorrhage in some patients. Although hantaviruses are infectious for endothelial cells and may cause direct injury, a large body of evidence suggests that immune mechanisms play an important role in the pathogenesis of HFRS.

Entities:  

Mesh:

Year:  1991        PMID: 1673261     DOI: 10.1093/clinids/13.1.97

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  46 in total

1.  Effects of tumor necrosis factor alpha on sin nombre virus infection in vitro.

Authors:  S F Khaiboullina; D M Netski; P Krumpe; S C St Jeor
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  The pathogenic NY-1 hantavirus G1 cytoplasmic tail inhibits RIG-I- and TBK-1-directed interferon responses.

Authors:  Peter J Alff; Irina N Gavrilovskaya; Elena Gorbunova; Karen Endriss; Yuson Chong; Erika Geimonen; Nandini Sen; Nancy C Reich; Erich R Mackow
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  [Transient myopia].

Authors:  A F Borkenstein; S Hausberger; C Mayer; C Faschinger
Journal:  Ophthalmologe       Date:  2011-07       Impact factor: 1.059

4.  Phage-displayed peptide targeting on the Puumala hantavirus neutralization site.

Authors:  T Heiskanen; A Lundkvist; A Vaheri; H Lankinen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Establishment of SYBR green-based qPCR assay for rapid evaluation and quantification for anti-Hantaan virus compounds in vitro and in suckling mice.

Authors:  Fei Wei; Jin-lin Li; Jia-xin Ling; Liang-Jun Chen; Ning Li; Yuan-Yuan Liu; Fan Luo; Hai-Rong Xiong; Wei Hou; Zhan-Qiu Yang
Journal:  Virus Genes       Date:  2012-10-10       Impact factor: 2.332

6.  Increased production of nitric oxide in patients with hemorrhagic fever with renal syndrome--relation to arterial hypotension and tumor necrosis factor.

Authors:  M Linderholm; P H Groeneveld; A Tärnvik
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

7.  The clinical spectrum of human hantavirus infection in Somerset, UK.

Authors:  J V Pether; G Lloyd
Journal:  Epidemiol Infect       Date:  1993-08       Impact factor: 2.451

8.  Hantaan virus infection of human endothelial cells.

Authors:  M N Pensiero; J B Sharefkin; C W Dieffenbach; J Hay
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

9.  Pulmonary involvement in nephropathia epidemica as demonstrated by computed tomography.

Authors:  M Linderholm; A Billström; B Settergren; A Tärnvik
Journal:  Infection       Date:  1992 Sep-Oct       Impact factor: 3.553

10.  The severity of Puumala hantavirus induced nephropathia epidemica can be better evaluated using plasma interleukin-6 than C-reactive protein determinations.

Authors:  Tuula K Outinen; Satu M Mäkelä; Ilpo O Ala-Houhala; Heini Sa Huhtala; Mikko Hurme; Antti S Paakkala; Ilkka H Pörsti; Jaana T Syrjänen; Jukka T Mustonen
Journal:  BMC Infect Dis       Date:  2010-05-25       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.